抗CTLA-4或PD-1治疗后眼部免疫相关不良事件:IRIS注册研究
基于美国眼科学会IRIS注册库的回顾性研究,纳入2013至2017年新诊断眼部免疫相关不良事件的患者,识别3123例接受抗CTLA-4或抗PD-1治疗者,其中112例出现眼部免疫相关不良事件。前葡萄膜炎最常见,各药物发病率不同,ICI治疗者眼部免疫相关不良事件发生率显著高于注册库一般人群,有葡萄膜炎或其他眼部炎症史者复发率高。结论强调早期协调眼科亚专科诊疗的重要性。
要点
- 接受ICI治疗者前葡萄膜炎发病率为3740/10万,高于一般人群(IRR 13.9)。
- 有其他葡萄膜炎者IRR达43.0,视乳头水肿IRR达38.3。
- 有葡萄膜炎或其他眼部炎症史者ICI治疗后复发率高达51.1%。
核心结论
- 接受ICI治疗的患者眼部免疫相关不良事件发生率高于整个注册库人群的眼部并发症发生率。
- 有既往自身免疫性眼病史的患者眼部并发症复发风险高,应早期协调眼科亚专科诊疗。
研究设计与样本
- 回顾性注册研究,数据来自美国眼科学会IRIS注册库参与眼科实践的电子健康记录。
- 纳入2013年1月1日至2017年12月31日新诊断眼部免疫相关不良事件的患者,通过ICD诊断代码识别。
- 主要暴露为既往启动免疫检查点抑制剂(ICI)治疗,共识别3123例接受抗CTLA-4或抗PD-1治疗的患者。
主要发现
- 3123例接受抗CTLA-4或抗PD-1治疗的患者中,112例出现眼部免疫相关不良事件。
- 前葡萄膜炎是最常见的眼部免疫相关不良事件,发病率:ipilimumab(抗CTLA-4)8209/10万,nivolumab(抗PD-1)2542/10万,pembrolizumab(抗PD-1)2451/10万,ipilimumab联合nivolumab 5556/10万,所有ICI合计3740/10万。
- 与整个注册库人群基线率相比,ICI治疗者眼部免疫相关不良事件发生率更高:前葡萄膜炎IRR 13.9,其他葡萄膜炎IRR 43.0,视乳头水肿IRR 38.3。
- 有葡萄膜炎或其他眼部炎症病史的患者启动ICI后眼部免疫相关不良事件复发率高达51.1%。
临床怎么用
- 对启动ICI治疗的患者,应早期协调眼科亚专科诊疗以管理眼部免疫相关不良事件。
- 有葡萄膜炎或其他眼部炎症病史的患者接受ICI治疗时需警惕眼部并发症复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Detailed study of ophthalmic immune-related adverse events (AEs), including determination of incidence and recurrence rates, is of integral importance in cancer immunotherapy to inform management and treatment guidelines. DESIGN: Retrospective registry study. PARTICIPANTS: Patients newly diagnosed with ophthalmic immune-related AEs between January 1, 2013, and December 31, 2017, in the American Academy of Ophthalmology's Intelligent Research in Sight (IRIS®) Registry. METHODS: Data were collected from electronic health records of IRIS® Registry participating ophthalmology practices. Patients with select ophthalmic immune-related AEs were identified by International Classification of Diseases diagnosis codes. The primary exposure of interest was prior initiation of immune checkpoint inhibitors (ICIs). MAIN OUTCOME MEASURES: Incidence of ophthalmic immune-related AEs within 1 year after initiation of ICI therapy was determined. Incidence rate ratios (IRRs) were derived by comparing incidence of ophthalmic immune-related AEs after ICIs versus rates of the same ocular complications in patients not taking ICIs in the entire registry population. Rates of ophthalmic immune-related AEs in patients with a past history of ocular inflammation or other specific ophthalmic condition before initiation of ICIs were examined further. RESULTS: A total of 3123 patients who received anti-CTLA-4 or anti-programmed cell death 1 (PD-1) therapy were identified, 112 of whom demonstrated an ophthalmic immune-related AE. Incidence rates for anterior uveitis, the most common ophthalmic immune-related AE, were 8209 per 100 000 for ipilimumab (anti-CTLA-4), 2542 per 100 000 for nivolumab (anti-PD-1), 2451 per 100 000 for pembrolizumab (anti-PD-1), 5556 per 100 000 for ipilimumab plus nivolumab, and 3740 per 100 000 among all ICIs. Rates of ophthalmic immune-related AEs among patients receiving ICI therapy were higher compared with baseline rates in the general registry population (anterior uveitis IRR, 13.9; other uveitis IRR, 43.0; papilledema IRR, 38.3). Patients with a history of uveitis or other ocular inflammatory condition demonstrated high recurrence rates of ophthalmic immune-related AEs after initiating ICIs (up to 51.1%). CONCLUSIONS: For patients initiating ICI therapy, early coordination with ophthalmic subspecialist care is important because rates of ophthalmic immune-related AEs are elevated compared with ocular complication rates in the entire registry population and patients with a history of prior autoimmune ocular disease are at high risk of recurrence of ocular complications.
引用
- Sun MM, Kelly SP, Mylavarapu Bs AL, et al. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Ophthalmology. 2020. PMID: 33166553. doi:10.1016/j.ophtha.2020.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。